BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
Credit Suisse upgrades Glenmark Pharmaceuticals to neutral
Expect earnings per share CAGR of 25 per cent over FY16-18. Consensus is yet to reflect the hit in Venezuela. Positive if conversion of profits to cash flows improves. Nitroglycerin launch in the fourth quarter of 2016 is a key catalyst.